Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Payables (2021 - 2025)

PAVmed has reported Payables over the past 5 years, most recently at $678000.0 for Q4 2025.

  • Quarterly results put Payables at $678000.0 for Q4 2025, up 3.2% from a year ago — trailing twelve months through Dec 2025 was $678000.0 (up 3.2% YoY), and the annual figure for FY2025 was $678000.0, up 3.2%.
  • Payables for Q4 2025 was $678000.0 at PAVmed, up from $342000.0 in the prior quarter.
  • Over the last five years, Payables for PAVM hit a ceiling of $8.2 million in Q1 2022 and a floor of $342000.0 in Q3 2025.
  • Median Payables over the past 5 years was $1.6 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Payables: skyrocketed 275.0% in 2022 and later tumbled 84.72% in 2023.
  • PAVmed's Payables stood at $3.3 million in 2021, then dropped by 18.04% to $2.7 million in 2022, then tumbled by 33.95% to $1.8 million in 2023, then crashed by 63.21% to $657000.0 in 2024, then grew by 3.2% to $678000.0 in 2025.
  • The last three reported values for Payables were $678000.0 (Q4 2025), $342000.0 (Q3 2025), and $387000.0 (Q2 2025) per Business Quant data.